PNTG Stock Forecast & Price Target

Pennant Gr is positioned favorably because its core home health and hospice business is delivering strong organic growth, with same-store Medicare home health admissions up 13.6% year over year, hospice ADC up 10.8%, and segment adjusted EBITDA margins improving despite wage pressure and prior reimbursement cuts. The company is also executing well on the former UNH/AMED integration ahead of schedule, with volume above expectations, clinical quality metrics improving where its EMR and best practices are fully deployed, and full integration now expected by mid-4Q26, while 2026 guidance was raised to revenue of $1,171.1MM-$1,190.1MM and adjusted EBITDA of $94.4MM-$98.0MM. Senior living adds another layer of support, with same-store occupancy at 81.6%, RevPOR up 5.5%, and margins improving, while a more favorable reimbursement backdrop in 2027 should further enhance margin flow-through across the platform.

Pennant Gr is viewed negatively because its sprawling, multi-state workforce faces sustainability and execution risks tied to varying clinical skill, licensure, and education levels, while the Home Health industry’s history of fraud, waste, and abuse raises compliance risk. The downside case also assumes integration headwinds in transitioning assets could force management to pause incremental M&A, limiting a key growth lever. If Home Health and Hospice revenue momentum plateaus and labor pressures intensify, margins could contract, leaving FY27E EBITDAR 5% below estimate and compressing the valuation multiple to 8.0x.